Fortress Biotech 경영진
경영진 기준 점검 3/4
Fortress Biotech CEO는 Lindsay Rosenwald, Dec2013 에 임명되었습니다 의 임기는 12.42 년입니다. 총 연간 보상은 $2.89M, 2.2% 급여 및 97.8% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $13.16M 가치에 해당하는 회사 주식의 14.1% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 7.7 년과 10.8 년입니다.
핵심 정보
Lindsay Rosenwald
최고경영자
US$2.9m
총 보수
| CEO 급여 비율 | 2.17% |
| CEO 재임 기간 | 12.4yrs |
| CEO 지분 보유율 | 14.1% |
| 경영진 평균 재임 기간 | 7.7yrs |
| 이사회 평균 재임 기간 | 10.8yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • 16h
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Summary Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. FBIO’s recent windfall from the Menkes disease drug sale positions it to easily pay $16 million in deferred FBIOP preferred dividends. FBIOP dividends, deferred for nearly two years, could total $4.69 per share if paid by June 15, 2026, benefiting significant insider holders. FBIO appears undervalued, with cash exceeding the sum of equity market cap, debt, preferred stock at par, and deferred dividends by $24 million. Read the full article on Seeking Alpha
내러티브 업데이트 • May 12
FBIO: Rare Pediatric Disease Voucher Will Support Future Upside Potential
Analysts have lifted their Fortress Biotech price target to $4.50 from $4.50, supported by updated assumptions around a slightly lower discount rate, adjusted revenue growth, an improved profit margin outlook, and a reduced future P/E multiple. Valuation Changes Fair Value: $4.50 is unchanged, with the target level held steady versus prior estimates.내러티브 업데이트 • Apr 25
FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around a fair value of $4.50, a discount rate of 8.80%, revenue growth of 44.56%, a profit margin of 12.79% and a future P/E of 9.24. Valuation Changes Fair Value: Maintained at $4.50, with no change in the estimated fair value per share.내러티브 업데이트 • Apr 11
FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to reflect updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. This has led to a revised target that is intended to better align with the company’s current risk and earnings outlook.내러티브 업데이트 • Mar 27
FBIO: Menkes Disease Breakthrough And Voucher Will Drive Future Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the overall fair value view steady. What's in the News FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, marking the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).내러티브 업데이트 • Mar 12
FBIO: Menkes Disease Approval And Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech, maintaining it at $4.50, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions that continue to support a similar fair value estimate. What's in the News Fortress Biotech and majority owned subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO (copper histidinate, formerly CUTX-101) to treat Menkes disease in pediatric patients, the first and only FDA approved treatment for this rare and often fatal condition (Key Developments).내러티브 업데이트 • Feb 26
FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Support Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech, reflecting updated views on revenue growth, profit margins, and future P/E assumptions, while keeping the underlying fair value estimate steady at $4.50. What's in the News The U.S. FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients.내러티브 업데이트 • Feb 11
FBIO: Menkes Disease Approval And Voucher Potential Will Drive Bullish Upside
Analysts have nudged their price target on Fortress Biotech higher to $4.50, reflecting updated assumptions around revenue growth, profit margins, and a slightly lower discount rate that together indicate a modestly stronger outlook for the company. What's in the News The U.S. Food and Drug Administration approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).분석 기사 • Feb 05
Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares have retraced a considerable 28% in the last month, reversing a fair...내러티브 업데이트 • Jan 28
FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Drive Bullish Outlook
Analysts have adjusted their price target on Fortress Biotech, reflecting updated assumptions on a discount rate, a profit margin of 65.99% and a future P/E of 1.53x. They are tying the change to a revised view of the company’s earnings power and risk profile.내러티브 업데이트 • Jan 12
FBIO: Resubmitted Menkes Therapy And Voucher Potential Will Shape Balanced Outlook
Analysts have adjusted their price target on Fortress Biotech to US$4.50, with the update mainly tied to refreshed assumptions around the discount rate, revenue growth near 48.3%, profit margin around 16.2% and a future P/E of about 6.17x. What's in the News Fortress Biotech and majority-owned subsidiary Cyprium Therapeutics had the resubmission of the New Drug Application for CUTX-101, a copper histidinate therapy for pediatric Menkes disease, accepted by the U.S. FDA as a Class 1 resubmission, with a new PDUFA target action date of January 14, 2026 (company announcement).내러티브 업데이트 • Dec 26
FBIO: FDA Progress On Rare Disease Therapy Will Drive Significant Upside Potential
Analysts have modestly lifted their price target on Fortress Biotech to $4.50 per share, citing slightly lower perceived risk, marginally stronger long term revenue growth, and a small improvement in projected profitability that together support a higher justified valuation multiple. What's in the News FDA accepts resubmission of the New Drug Application for CUTX-101 for Menkes disease as a Class 1 resubmission, setting a new PDUFA target action date of January 14, 2026 (Key Developments) Earlier FDA Complete Response Letter for CUTX-101 cited cGMP compliance issues at the manufacturing site but raised no concerns with the drug's efficacy or safety data (Key Developments) Sentynl Therapeutics now holds full responsibility for development and commercialization of CUTX-101, with Cyprium eligible for royalties, up to $129 million in milestones, and a potential Rare Pediatric Disease Priority Review Voucher upon approval (Key Developments) CUTX-101 NDA, initially granted Priority Review, is supported by positive topline data showing significant improvement in overall survival in Menkes disease patients treated early (Key Developments) Valuation Changes Fair Value: unchanged at $4.50 per share, reflecting a stable central valuation despite minor model adjustments Discount Rate: decreased slightly from 8.36 percent to 8.07 percent, indicating a modest reduction in perceived risk Revenue Growth: increased slightly from 46.90 percent to 47.54 percent, reflecting marginally stronger long term growth expectations Net Profit Margin: increased slightly from 16.03 percent to 16.24 percent, pointing to a small improvement in projected profitability Future P/E: declined modestly from 6.51x to 6.29x, suggesting a slightly lower multiple applied to future earnings분석 기사 • Dec 16
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 27% in...내러티브 업데이트 • Dec 12
FBIO: Menkes Drug Clearance Of Manufacturing Issues Will Unlock Significant Upside Potential
Analysts have modestly raised their price target on Fortress Biotech to reflect a slightly higher fair value estimate of $4.50 per share, supported by expectations for stronger revenue growth and only a modest adjustment to discount rates and future valuation multiples. What's in the News The FDA issued a Complete Response Letter for the CUTX-101 New Drug Application for Menkes disease, citing cGMP deficiencies at the manufacturing facility but raising no concerns about efficacy or safety data.분석 기사 • Oct 05
Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive
The Fortress Biotech, Inc. ( NASDAQ:FBIO ) share price has softened a substantial 26% over the previous 30 days...
내러티브 업데이트 • Aug 19
FDA Approval Will Open $1 Billion Dermatology Market
Despite increased revenue growth forecasts, Fortress Biotech’s consensus price target was lowered from $10.00 to $8.00 amid a sharply reduced future P/E, indicating a more cautious outlook on profitability relative to anticipated sales growth. What's in the News Fortress Biotech was dropped from the Russell Microcap Growth Benchmark Index.분석 기사 • Aug 17
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks
With a price-to-sales (or "P/S") ratio of 1.1x Fortress Biotech, Inc. ( NASDAQ:FBIO ) may be sending very bullish...새로운 내러티브 • Jul 06
FDA Approval Will Open $1 Billion Dermatology Market
Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.분석 기사 • Mar 11
Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy...분석 기사 • Oct 29
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry
Those holding Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares would be relieved that the share price has rebounded 36% in...분석 기사 • Jul 26
Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders have had their patience rewarded with a 54% share price jump in the...분석 기사 • Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 99% in...분석 기사 • Aug 18
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$119m |
| Dec 31 2025 | US$3m | US$63k | -US$2m |
| Sep 30 2025 | n/a | n/a | -US$5m |
| Jun 30 2025 | n/a | n/a | -US$24m |
| Mar 31 2025 | n/a | n/a | -US$51m |
| Dec 31 2024 | US$1m | US$63k | -US$56m |
| Sep 30 2024 | n/a | n/a | -US$58m |
| Jun 30 2024 | n/a | n/a | -US$49m |
| Mar 31 2024 | n/a | n/a | -US$63m |
| Dec 31 2023 | US$1m | US$63k | -US$69m |
| Sep 30 2023 | n/a | n/a | -US$86m |
| Jun 30 2023 | n/a | n/a | -US$104m |
| Mar 31 2023 | n/a | n/a | -US$100m |
| Dec 31 2022 | US$1m | US$63k | -US$95m |
| Sep 30 2022 | n/a | n/a | -US$97m |
| Jun 30 2022 | n/a | n/a | -US$93m |
| Mar 31 2022 | n/a | n/a | -US$74m |
| Dec 31 2021 | US$3m | US$60k | -US$65m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$33m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$3m | US$59k | -US$47m |
| Sep 30 2020 | n/a | n/a | -US$57m |
| Jun 30 2020 | n/a | n/a | -US$54m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$1m | US$32k | -US$40m |
보상 대 시장: Lindsay의 총 보수(USD2.89M)는 US 시장에서 비슷한 규모 기업의 평균(USD629.02K)보다 높습니다.
보상과 수익: Lindsay의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Lindsay Rosenwald (70 yo)
12.4yrs
재임 기간
US$2,887,257
보수
Dr. Lindsay Allan Rosenwald, M.D. serves as Director of Urica Therapeutics, Inc. He serves as Director at Caelum Biosciences, Inc. He serves as an Executive Chairman of Journey Medical Corporation since Oc...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chairman | 12.4yrs | US$2.89m | 14.1% $ 13.2m | |
| CFO & Head of Corporate Development | 6yrs | US$664.08k | 0.065% $ 60.6k | |
| Chief Strategy Officer | 1.1yrs | US$115.00k | 0% $ 0 | |
| Executive Vice Chairman of Strategic Development & Director | 12.3yrs | US$2.44m | 6.85% $ 6.4m | |
| General Counsel & Corporate Secretary | 7.7yrs | 데이터 없음 | 데이터 없음 |
7.7yrs
평균 재임 기간
54.5yo
평균 나이
경험이 풍부한 관리: FBIO의 경영진은 노련하고 경험이 풍부합니다(평균 재임 7.7 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chairman | 16.6yrs | US$2.89m | 14.1% $ 13.2m | |
| Executive Vice Chairman of Strategic Development & Director | 12.4yrs | US$2.44m | 6.85% $ 6.4m | |
| Independent Director | 12.3yrs | US$135.00k | 0.19% $ 177.7k | |
| Scientific Advisor | 8.9yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 10.8yrs | US$200.00k | 0.083% $ 77.1k | |
| Scientific Advisor | 8.9yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 19.9yrs | US$167.50k | 0.35% $ 325.1k | |
| Scientific Advisor | 8.9yrs | 데이터 없음 | 데이터 없음 | |
| Scientific Advisor | 8.9yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 17.4yrs | US$147.50k | 0.010% $ 9.4k | |
| Scientific Advisor | 8.9yrs | 데이터 없음 | 데이터 없음 |
10.8yrs
평균 재임 기간
70yo
평균 나이
경험이 풍부한 이사회: FBIO의 이사회는 노련하고 경험이 풍부합니다(평균 재임 10.8 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/29 13:56 |
| 종가 | 2026/05/29 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Fortress Biotech, Inc.는 13명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |